IAA Journal of Applied Sciences 12(1):21-24, 2024.
©IAAJOURNALS
https://doi.org/10.59298/IAAJAS/2024/121.21240

www.iaajournals.org
ISSN: 2636-7246
IAAJAS: 121.21240

Pharmacogenomics of Lipid-Lowering Therapies in Obese Individuals with Dyslipidemia

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Dyslipidemia is a key contributor to cardiovascular diseases, especially in obese individuals, where lipid metabolism is frequently impaired. Lipid-lowering therapies, such as statins, fibrates, and PCSK9 inhibitors, are commonly prescribed to manage dyslipidemia, but their efficacy and adverse effect profiles vary significantly across individuals. Pharmacogenomics, the study of how genetic variations influence drug response, has emerged as a powerful tool in predicting these inter-individual differences and optimizing treatment regimens. In obese individuals, genetic polymorphisms in genes involved in lipid metabolism, such as SLCO1B1, CYP3A4, APOE, and LDLR, have been linked to variable responses to lipid-lowering drugs. This review explores the impact of pharmacogenomics on lipid-lowering therapies in obese individuals with dyslipidemia, emphasizing the potential of personalized medicine in improving therapeutic outcomes. By understanding genetic influences on drug efficacy and safety, clinicians can tailor treatments to individual patients, thereby reducing adverse effects and improving lipid control. We also highlight current challenges in translating pharmacogenomic findings into clinical practice and discuss the future directions of this emerging field.

Keywords: Pharmacogenomics, Lipid-Lowering Therapies, Dyslipidemia, Obesity, Statins, Fibrates, PCSK9 Inhibitors

INTRODUCTION

Dyslipidemia, characterized by abnormal levels of lipids in the blood, including elevated low-density lipoprotein cholesterol (LDL-C), triglycerides, and decreased high-density lipoprotein cholesterol (HDL-C), is a well-established risk factor for cardiovascular diseases (CVD), such as atherosclerosis, stroke, and myocardial infarction[1–4]. The pathophysiology of dyslipidemia is particularly concerning in obese individuals, as obesity itself is often accompanied by metabolic disturbances that further exacerbate lipid abnormalities [5]. This dysregulation of lipid metabolism not only contributes to increased cardiovascular risk but also complicates the management of these individuals. In obesity, excess adipose tissue leads to a state of chronic low-grade inflammation, insulin resistance, and altered lipid processing in the liver and other tissues. This results in elevated LDL-C and triglycerides, as well as decreased HDL-C, thereby intensifying the risk of CVD[6]. Given the strong link between dyslipidemia and cardiovascular events, lipid-lowering therapies such as statins, fibrates, ezetimibe, and PCSK9 inhibitors are commonly used to manage lipid levels and prevent atherosclerosis and its complications [7].

However, current lipid-lowering therapies often employ a "one-size-fits-all" approach, where treatment regimens are applied universally without accounting for individual genetic differences. While this method is effective for many, it frequently results in variable outcomes due to the presence of inter-individual variability in drug response, particularly in high-risk populations like obese individuals. Factors such as drug metabolism, efficacy, and susceptibility to adverse effects are largely influenced by genetic differences, leading to suboptimal results in certain patients[8–10]. Pharmacogenomics, the study of how genes influence an individual's response to drugs, offers a promising solution to this variability by enabling personalized treatment strategies. This approach can help identify genetic polymorphisms that affect the pharmacokinetics and pharmacodynamics of lipid-lowering medications.[11, 12] For example, variations in genes such as SLCO1B1 (which influences statin metabolism), PCSK9 (involved in LDL receptor degradation), and ABCG5/8 (related to cholesterol

absorption and transport) have been shown to impact the effectiveness and safety of lipid-lowering therapies [13].

By incorporating pharmacogenomic insights, clinicians can tailor lipid-lowering treatments to the individual's genetic profile, thereby optimizing therapeutic efficacy while minimizing adverse effects[14]. This is particularly important for obese individuals, who are not only at higher risk of dyslipidemia but also may have altered drug metabolism due to changes in body composition and hepatic function[14]. Personalized treatment strategies could improve outcomes by ensuring that lipid-lowering therapies are both more effective and better tolerated, ultimately reducing the burden of cardiovascular disease in obese populations. In the future, widespread use of pharmacogenomic testing in clinical practice could help stratify patients based on their genetic predispositions, leading to more precise and effective lipid management. This would mark a significant step forward in personalized medicine, ensuring that therapies are tailored to the unique biological makeup of each individual, particularly those at high risk, such as obese patients with dyslipidemia.

Lipid-Lowering Therapies: Overview

The most commonly used lipid-lowering agents include:

Statins, HMG-CoA reductase inhibitors, primarily lower LDL-C[15]; fibrates, peroxisome proliferator-activated receptor alpha (PPARα) agonists, are effective in reducing triglycerides[16]; PCSK9 inhibitors, monoclonal antibodies, enhance LDL receptor activity, lowering LDL-C levels; and ezetimibe reduces intestinal cholesterol absorption[17]. Despite their efficacy, these therapies exhibit variable responses across populations, often leading to suboptimal outcomes in certain individuals. Pharmacogenomics aims to bridge this gap by identifying genetic markers associated with differential drug responses.

Genetic Polymorphisms and Statin Response

Statins are the first-line therapy for dyslipidemia, particularly in obese patients with a high cardiovascular risk. However, genetic polymorphisms significantly affect statin metabolism, efficacy, and the risk of adverse effects.[18–21]

SLCO1B1 polymorphisms: Variants in this gene affect the hepatic uptake of statins, particularly simvastatin. The SLCO1B1 c.521T>C polymorphism is strongly associated with increased risk of statin-induced myopathy.

CYP3A4 and CYP3A5: These cytochrome P450 enzymes metabolize statins such as atorvastatin and simvastatin. Polymorphisms in these genes can lead to either reduced drug efficacy or increased side effects.

APOE polymorphisms: APOE variants influence lipid levels and statin response. The APOE ε4 allele has been associated with a less favorable response to statins.

Pharmacogenomics of Fibrates and PCSK9 Inhibitors

PPARα polymorphisms: Fibrates activate PPARα, which plays a central role in lipid metabolism. Genetic variations in PPARα can modulate the lipid-lowering effect of fibrates, particularly in triglyceride levels.

LDLR mutations: PCSK9 inhibitors rely on the LDL receptor pathway for their lipid-lowering effects. Variants in the LDLR gene can affect the receptor's function, influencing the efficacy of PCSK9 inhibitors.

Obesity, Dyslipidemia, and Gene-Environment Interactions

Obesity induces a complex interplay between genetic and environmental factors that exacerbate dyslipidemia. Obesity-related inflammation, insulin resistance, and altered adipokine levels interact with genetic predispositions to influence lipid metabolism and drug responses [22] For instance, inflammation may affect the expression of genes involved in lipid metabolism, further complicating the pharmacogenomic landscape.

Challenges in Implementing Pharmacogenomics in Clinical Practice

Despite promising research, the integration of pharmacogenomics into routine clinical practice faces several hurdles: Genetic variability across populations poses a significant challenge in pharmacogenomics, as many studies are conducted within specific ethnic groups, which limits the generalizability and applicability of their findings to diverse populations worldwide. Additionally, the high cost and limited accessibility of genetic testing present a major barrier, as widespread implementation of pharmacogenomic testing remains financially unfeasible in many healthcare systems. Furthermore, the complexity of gene-drug interactions adds another layer of difficulty, as multiple genes, along with environmental factors, influence drug responses, making it challenging to integrate pharmacogenomics into personalized medicine effectively [23, 24].

Future Directions and Conclusion

The field of pharmacogenomics holds immense potential for the development of personalized lipid-lowering therapies in obese individuals with dyslipidemia. Future research should focus on

large-scale, multi-ethnic genome-wide association studies (GWAS) to identify novel genetic markers and develop cost-effective pharmacogenomic testing strategies. Integrating pharmacogenomics with clinical decision-making tools will enable healthcare providers to optimize treatment for individuals, reducing the risk of adverse effects while improving lipid profiles.

REFERENCES

1. Uti, D.E., Ibiam, U.A., Omang, W.A., Udeozor, P.A., Umoru, G.U., Nwadum, S.K., Bawa, I., Alum, E.U., Mordi, J.C., Okoro, E.O., Obeten, U.N., Onwe, E.N., Zakari, S., Opotu, O.R., Aja, P.M.: Buchholzia coriacea Leaves Attenuated Dyslipidemia and Oxidative Stress in Hyperlipidemic Rats and Its Potential Targets in Silico. Pharmaceutical Fronts. 05, e141–e152 (2023). https://doi.org/10.1055/s-0043-1772607
2. Calcaterra, V., Vandoni, M., Rossi, V., Berardo, C., Grazi, R., Cordaro, E., Tranfaglia, V., Carnevale Pellino, V., Cereda, C., Zuccotti, G.: Use of Physical Activity and Exercise to Reduce Inflammation in Children and Adolescents with Obesity. Int J Environ Res Public Health. 19, 6908 (2022). https://doi.org/10.3390/ijerph19116908
3. Arvanitis, M., Lowenstein, C.J.: Dyslipidemia. Ann Intern Med. 176, ITC81–ITC96 (2023). https://doi.org/10.7326/AITC202306200
4. Aja, P.M., Chiadikaobi, C.D., Agu, P.C., Ale, B.A., Ani, O.G., Ekpono, E.U., Ogwoni, H.A., Awoke, J.N., Ogbu, P.N., Aja, L., Nwite, F.E., Ukachi, O.U., Orji, O.U., Nweke, P.C., Egwu, C.O., Ekpono, E.U., Ewa, G.O., Igwenyi, I.O., Tusubira, D., Offor, C.E., Maduagwuna, E.K., Alum, E.U., Uti, D.E., Njoku, A., Atoki, V.A., Awuchi, C.G.: Cucumeropsis mannii seed oil ameliorates Bisphenol-A-induced adipokines dysfunctions and dyslipidemia. Food Sci Nutr. 11, 2642–2653 (2023). https://doi.org/10.1002/fsn3.3271
5. Islam, S., AshiqurRahman, Md., AnamChowdhury, S., Rahaman, S.: A review: Serum Lipid Profile Status in Cardiovascular Disease. MMR. 1, 135 (2023). https://doi.org/10.59429/mmr.v1i1.135
6. Wazir, M., Olanrewaju, O.A., Yahya, M., Kumari, J., Kumar, N., Singh, J., Abbas Al-itbi, A.Y., Kumari, K., Ahmed, A., Islam, T., Varrassi, G., Khatri, M., Kumar, S., Wazir, H., Raza, S.S.: Lipid Disorders and Cardiovascular Risk: A Comprehensive Analysis of Current Perspectives. Cureus. (2023). https://doi.org/10.7759/cureus.51395
7. Dugré, N., Lindblad, A.J., Perry, D., Allan, G.M., Braschi, É., Falk, J., Froentjes, L., Garrison, S.R., Kirkwood, J.E.M., Korownyk, C.S., McCormack, J.P., Moe, S.S., Paige, A., Potter, J., Thomas, B.S., Ton, J., Young, J., Weresch, J., Kolber, M.R.: Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews. Can Fam Physician. 69, 701–711 (2023). https://doi.org/10.46747/cfp.6910701
8. Masana, L., Plana, N., Andreychuk, N., Ibarretxe, D.: Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. Pharmacological Research. 190, 106738 (2023). https://doi.org/10.1016/j.phrs.2023.106738
9. Gunta, S.P., O'Keefe, J.H., O'Keefe, E.L., Lavie, C.J.: PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients. Progress in Cardiovascular Diseases. 79, 12–18 (2023). https://doi.org/10.1016/j.pcad.2023.02.007
10. El Hussein, M.T., Sharma, A., Parmar, K., Shelat, K.: Pharmacotherapeutics for dyslipidemia management. The Nurse Practitioner. 48, 36–47 (2023). https://doi.org/10.1097/01.NPR.0000000000000059
11. Oates, J.T., Lopez, D.: Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application. International journal of biomedical investigation. 1, 111 (2018). https://doi.org/10.31531/2581-4745.1000111
12. Qahwaji, R., Ashankyty, I., Sannan, N.S., Hazzazi, M.S., Basabrain, A.A., Mobashir, M.: Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. Pharmaceuticals. 17, 940 (2024). https://doi.org/10.3390/ph17070940
13. Spolitu, S., Dai, W., Zadroga, J.A., Ozcan, L.: PCSK9 and Lipid Metabolism. Current opinion in lipidology. 30, 186 (2019). https://doi.org/10.1097/MOL.0000000000000601
14. Hindi, N.N., Alenbawi, J., Nemer, G.: Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia. Journal of Personalized Medicine. 11, 877 (2021). https://doi.org/10.3390/jpm11090877
15. Sizar, O., Khare, S., Patel, P., Talati, R.: Statin Medications. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2024)
16. Gandotra, P., Miller, M.: CHAPTER 13 - The Role of High-Density Lipoprotein Cholesterol in the Development of Atherosclerotic Cardiovascular Disease. In: Blumenthal, R.S.,

Foody, J.M., and Wong, N.D. (eds.) Preventive Cardiology: Companion to Braunwald's Heart Disease. pp. 204–214. W.B. Saunders, Philadelphia (2011)
17. Safarova, M., Bimal, T., Soffer, D.E., Hirsh, B., Shapiro, M.D., Mintz, G., Cha, A., Gianos, E.: Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond. American Journal of Preventive Cardiology. 19, 100701 (2024). https://doi.org/10.1016/j.ajpc.2024.100701
18. Rossini, E., Biscetti, F., Rando, M.M., Nardella, E., Cecchini, A.L., Nicolazzi, M.A., Covino, M., Gasbarrini, A., Massetti, M., Flex, A.: Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter? International Journal of Molecular Sciences. 23, 9326 (2022). https://doi.org/10.3390/ijms23169326
19. Sivkov, A., Chernus, N., Gorenkov, R., Sivkov, S., Sivkova, S., Savina, T.: Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia. Lipids in Health and Disease. 20, 157 (2021). https://doi.org/10.1186/s12944-021-01586-7
20. Shamsudin, A.F., Sulong, S., Ahmad, I., Bakar, N.S.: Association between genetic polymorphisms and other attributing factors with lipid profiles among statin users: a cross-sectional retrospective study. Egyptian Journal of Medical Human Genetics. 25, 53 (2024). https://doi.org/10.1186/s43042-024-00523-4
21. Soppert, J., Lehrke, M., Marx, N., Jankowski, J., Noels, H.: Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews. 159, 4–33 (2020). https://doi.org/10.1016/j.addr.2020.07.019
22. Wondmkun, Y.T.: Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes. 13, 3611–3616 (2020). https://doi.org/10.2147/DMSO.S275898
23. Cicali, E.J., Weitzel, K.W., Elsey, A.R., Orlando, F.A., Vinson, M., Mosley, S., Smith, D.M., Davis, R., Drum, L., Estores, D., Franciosi, J.P., Hagen, M.G., Jerkins, G.J., Mercado, E.S., Nainaparampil, J., Padron, A., Rosenberg, E.I., Wright, A., Schmidt, S.O., Mathews, C.A., Cavallari, L.H., Johnson, J.A.: Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene–drug pairs across ambulatory care settings. Genetics in Medicine. 21, 2264–2274 (2019). https://doi.org/10.1038/s41436-019-0500-7
24. Bienfait, K., Chhibber, A., Marshall, J.-C., Armstrong, M., Cox, C., Shaw, P.M., Paulding, C.: Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Hum Genet. 141, 1165–1173 (2022). https://doi.org/10.1007/s00439-021-02282-3

CITE AS: Kato Jumba K. (2024). Pharmacogenomics of Lipid-Lowering Therapies in Obese Individuals with Dyslipidemia. IAA Journal of Applied Sciences 12(1):21-24. https://doi.org/10.59298/IAAJAS/2024/121.21240